Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
JAMA Netw Open ; 6(12): e2346872, 2023 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-38064222

RESUMO

Importance: Systematic reviews and meta-analyses often report conflicting results when assessing evidence for probiotic efficacy, partially because of the lack of understanding of the unique features of probiotic trials. As a consequence, clinical decisions on the use of probiotics have been confusing. Objective: To provide recommendations to improve the quality and consistency of systematic reviews with meta-analyses on probiotics, so evidence-based clinical decisions can be made with more clarity. Evidence Review: For this consensus statement, an updated literature review was conducted (January 1, 2020, to June 30, 2022) to supplement a previously published 2018 literature search to identify areas where probiotic systematic reviews with meta-analyses might be improved. An expert panel of 21 scientists and physicians with experience on writing and reviewing probiotic reviews and meta-analyses was convened and used a modified Delphi method to develop recommendations for future probiotic reviews. Findings: A total of 206 systematic reviews with meta-analysis components on probiotics were screened and representative examples discussed to determine areas for improvement. The expert panel initially identified 36 items that were inconsistently reported or were considered important to consider in probiotic meta-analyses. Of these, a consensus was reached for 9 recommendations to improve the quality of future probiotic meta-analyses. Conclusions and Relevance: In this study, the expert panel reached a consensus on 9 recommendations that should promote improved reporting of probiotic systematic reviews with meta-analyses and, thereby, assist in clinical decisions regarding the use of probiotics.


Assuntos
Probióticos , Humanos , Consenso , Suplementos Nutricionais , Probióticos/uso terapêutico , Revisões Sistemáticas como Assunto , Metanálise como Assunto
3.
Semin Liver Dis ; 28(4): 396-406, 2008 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-18956296

RESUMO

The prevalence of obesity and the metabolic syndrome (MS) is on the rise, and subsequently the hepatic manifestation of MS, nonalcoholic fatty liver disease (NAFLD), has become a common entity in clinical practice. Most patients with NAFLD face medical complications related to their underlying MS in other organ systems; however, a small but significant group of patients with the more aggressive form of fatty liver, nonalcoholic steatohepatitis (NASH), are at risk of developing cirrhosis and hepatocellular carcinoma. As patients are generally asymptomatic, often their disease goes unrecognized. This is particularly true for NASH, where liver biopsy is currently required to make the diagnosis. Once diagnosed, no one treatment has been shown to be universally efficacious and those that are of benefit are not without side effects. Effective treatment regimens directed at both decreasing insulin resistance as well as the processes leading to necroinflammation and hepatic fibrosis have been investigated and include lifestyle modification, surgical therapies, and pharmacotherapy. This review focuses on current and potential future therapies for NASH.


Assuntos
Fígado Gorduroso/terapia , Animais , Antioxidantes/uso terapêutico , Cirurgia Bariátrica , Índice de Massa Corporal , Canabinoides/antagonistas & inibidores , Colagogos e Coleréticos/uso terapêutico , Comorbidade , Fígado Gorduroso/tratamento farmacológico , Fígado Gorduroso/epidemiologia , Fígado Gorduroso/metabolismo , Fígado Gorduroso/fisiopatologia , Peptídeo 1 Semelhante ao Glucagon/análogos & derivados , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hipoglicemiantes/uso terapêutico , Resistência à Insulina , Lactonas/uso terapêutico , Estilo de Vida , Metformina/uso terapêutico , Obesidade/tratamento farmacológico , Obesidade/epidemiologia , Orlistate , Piperidinas/uso terapêutico , Pirazóis/uso terapêutico , Rimonabanto , Tiazolidinedionas/uso terapêutico , Resultado do Tratamento , Ácido Ursodesoxicólico/uso terapêutico , Redução de Peso
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA